Presidio Medical, Inc., a South San Francisco, CA-based global clinical-stage medical device company developing a transformational Ultra Low Frequency (ULF™) neuromodulation platform, closed a $72m Series C funding.
The round was led by Deerfield Management, existing investors Invus Opportunities and Action Potential Venture Capital, and joined by ShangBay Capital. In conjunction with this financing David Neustaedter, Ph.D., Venture Partner, Deerfield Management Company, has joined Presidio’s Board of Directors.
Proceeds will be used to expand the team, scale manufacturing, and conduct long-term, pivotal clinical studies of its ULF™ SCS system.
Led by Michael Onuscheck, Chairman and CEO, Presidio Medical is a clinical-stage medical device company developing a transformational neuromodulation platform to treat diseases of undesired neural activity with a first indication in the treatment of chronic pain.
FinSMEs
26/06/2023